References
- Beckingsale AB, Davies J, Gibson JM, Rosenthal AR. Acute anterior uveitis, ankylosing spondylitis, back pain, and HLA-B27. Br J Ophthalmol. 1984;68(10):741–745. doi:10.1136/bjo.68.10.741.
- Bañares A, Hernández-García C, Fernández-Gutiérrez B, Jover JA. Eye involvement in the spondyloarthropathies. Rheum Dis Clin North Am. 1998;24(4):771–84, ix. doi:10.1016/S0889-857X(05)70041-7.
- van der Veer EG, Keunen JE, Severe RA. HLA B27-associated uveitis complicated by hypotony, serous retinal detachment, and ciliochoroidal effusion. Ocul Immunol Inflamm. 2014;22(1):23–26. doi:10.3109/09273948.2013.828081.
- Rodriguez A, Akova YA, Pedroza-Seres M, Foster CS. Posterior segment ocular manifestations in patients with HLA-B27-associated uveitis. Ophthalmology. 1994;101(7):1267–1274. doi:10.1016/S0161-6420(94)31179-1.
- Dodds EM, Lowder CY, Meisler DM. Posterior segment inflammation in HLA-B27+ acute anterior uveitis: clinical characteristics. Ocul Immunol Inflamm. 1999;7(2):85–92. doi:10.1076/ocii.7.2.85.4015.
- Gueudry J, Thorne JE, Bansie R, Braun J, van Hagen PM, Bodaghi B. Biologic therapy for HLA-B27-associated ocular disorders. Ocul Immunol Inflamm. 2017;25(2):169–178. doi:10.1080/09273948.2016.1234625.
- Sharma SM, Nestel AR, Lee RWJ, Dick AD. Clinical review: anti-TNFalpha therapies in uveitis: perspective on 5 years of clinical experience. Ocul Immunol Inflamm. 2009;17(6):403–414. doi:10.3109/09273940903072443.
- Jabs DA, Nussenblatt RB, Rosenbaum JT. Standardization of Uveitis Nomenclature (SUN) working group. Standardization of uveitis nomenclature for reporting clinical data. results of the first international workshop. Am J Ophthalmol. 2005;140:509–516.
- Jabs DA, Rosenbaum JT, Foster CS, et al. Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. Am J Ophthalmol. 2000;130(4):492–513. doi:10.1016/S0002-9394(00)00659-0.
- Miserocchi E, Modorati G, Pontikaki I, Meroni PL, Gerloni V. Long-term treatment with golimumab for severe uveitis. Ocul Immunol Inflamm. 2014;22(2):90–95. doi:10.3109/09273948.2013.844265.
- D’Ambrosio EM, La Cava M, Tortorella P, Gharbiya M, Campanella M, Iannetti L. Clinical features and complications of the HLA-B27-associated acute anterior uveitis: a metanalysis. Semin Ophthalmol. 2017;32(6):689–701.
- Misiuk-Hojło M, Międzybrodzki R, Grzybowski A, et al. Elevated levels of anti-endotoxin antibodies in patients with bilateral idiopathic acute anterior uveitis. Acta Ophthalmol (Copenh). 2011;89(3):e283–288. doi:10.1111/aos.2011.89.issue-3.
- Ruiz-Medrano J, Díaz-Valle D, Cuiña R, et al. The role of tocilizumab in the treatment of inflammatory diseases of the eye and orbit: A useful alternative. J Fr Ophtalmol. 2018;41(8):759–766. doi:10.1016/j.jfo.2018.02.006.
- Markomichelakis NN, Theodossiadis PG, Pantelia E, Papaefthimiou S, Theodossiadis GP, Sfikakis PP. Infliximab for chronic cystoid macular edema associated with uveitis. Am J Ophthalmol. 2004;138(4):648–650. doi:10.1016/j.ajo.2004.04.066.
- Barry RJ, Tallouzi MO, Bucknall N, et al. Anti-tumour necrosis factor biological therapies for the treatment of uveitic macular oedema (UMO) for non-infectious uveitis. Cochrane Database Syst Rev. 2018;12:CD012577.
- Ku W-N, Lin C-J, Tsai -Y-Y. The rescue effect of adalimumab in the treatment of refractory pediatric panuveitis complicated with steroid-induced glaucoma. Taiwan J Ophthalmol. 2018;8(3):164–167. doi:10.4103/tjo.tjo_63_17.
- Dutta Majumder P, Jayshree DRL, Kaushik V. A case of idiopathic necrotizing scleritis with secondary glaucoma treated successfully with golimumab and Ahmed valve implantation. Indian J Ophthalmol. 2019 Aug;67(8):1360–1362. doi:10.4103/ijo.IJO_2081_18.
- Vaidya H, Dutta Majumder P, Biswas J. Presumed tubercular choroidal nodule following adalimumab therapy for juvenile idiopathic arthritis. Indian J Ophthalmol. 2019;67(3):399–400. doi:10.4103/ijo.IJO_1149_18.
- Dixon WG, Hyrich KL, Watson KD, et al. Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR). Ann Rheum Dis. 2010;69(3):522–528. doi:10.1136/ard.2009.118935.